The cancer therapeutics developer has followed up an Eli Lilly-backed first close with an extra $25m, taking the round to $82.6m.

The all-cash deal will provide an exit for Massachusetts Mutual Life when formally JLL takes over the property management platform developer.

Novartis Venture Fund and Hikma Ventures are set to exit the online medical treatment provider in a cash-and-stock purchase by 23andme.

The digital therapeutics developer closed a series B round that included corporate venturing units and existing investors Hikma Ventures and Sanofi Ventures.

Online insurance provider Justos raised $35.8m in a SoftBank-led series A round while social game studio GreenPark Sports closed a $31m series B that included Alameda Research.

The RTL and Mediaocean-backed advertising technology provider increased its valuation to $1.4bn in a round which will help it increase staff numbers.

Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.

Blue Venture Fund and CVS Health Ventures helped the telemedicine system developer raise funding which will boost its expansion into new markets and expand its treatment offering.

The market communicationns platform developer is going public today in an $81m initial public offering which will enable OpenText to exit.

DraftKings was among the limited partners for the firm's oversubscribed debut fund, as were The Kraft Group, Madison Square Garden Sports and Madison Square Garden Entertainment.